MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series
- 98 Downloads
MiRNAs are small endogenous non-coding RNAs implicated with gene expression regulation. Changes in miRNA levels have been reported in thyroid cancer. Fine-needle aspiration cytology (FNAC) is the most reliable tool for differential diagnosis of thyroid nodules.
We have analyzed 174 FNAC from 168 patients with thyroid nodules for expression levels of 11 miRNAs (miRNA197; -187; -181b-3p; -181b-5p; -224; -181a; 146b; -221; -222; -155 and miRNA183) known to be up-regulated in cancer tissues compared to benign lesions. Expression of miRNAs was analyzed in FNA samples calculating the fold change of miRNA expression relative to normal thyroid tissue after normalization to an endogenous control.
In FNAC, miRNA expression was confirmed to be higher in malignant or suspicious for malignancy nodules compared to benign, only for miRNA146b, -222 and -221 (fold change expression ≥ 5).
In this study, we confirmed that a limited set of miRNAs can be used for the differential diagnosis of thyroid nodules.
KeywordsFine-needle aspiration cytology miRNA221 miRNA222 miRNA146b Thyroid cancer
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in this study involving human participants were in accordance with local ethical committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent has been required and signed by each participant to the study.
- 1.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 26:1–133. https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentralGoogle Scholar
- 2.Pishkari S, Paryan M, Hashemi M, Baldini E, Mohammadi-Yeganeh S (2017) The role of microRNAs in different types of thyroid carcinoma: a comprehensive analysis to find new miRNA supplementary therapies. J Endocrinol Invest. https://doi.org/10.1007/s40618-017-0735-6 (Epub ahead of print) CrossRefPubMedGoogle Scholar
- 4.Agretti P, Ferrarini E, Rago T, Candelieri A, De Marco G, Dimida A, Niccolai F, Molinaro A, Di Coscio G, Pinchera A, Vitti P, Tonacchera M (2012) MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. Eur J Endocrinol 167:393–400. https://doi.org/10.1530/EJE-12-0400 CrossRefPubMedGoogle Scholar
- 5.Paskaš S, Janković J, Živaljević V, Tatić S, Božić V, Nikolić A, Radojković D, Savin S, Cvejić D (2015) Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing. Cancer Cytopathol. 123:471–479. https://doi.org/10.1002/cncy.21554 CrossRefPubMedGoogle Scholar
- 6.Panebianco F, Mazzanti C, Tomei S, Aretini P, Franceschi S, Lessi F, Di Coscio G, Bevilacqua G, Marchetti I (2015) The combination of four molecular markers improves thyroid cancer cytologic diagnosis and patient management. BMC Cancer. 15:918. https://doi.org/10.1186/s12885-015-1917-2 CrossRefPubMedPubMedCentralGoogle Scholar